Congressional briefing highlights connection between psoriasis, psoriatic arthritis and other health risks
In recent years, research into psoriasis and psoriatic arthritis has shed light into the systemic, whole-body effects of psoriatic diseases and the increased risk for heart disease, diabetes and other chronic conditions for patients. The National Psoriasis Foundation and the American Heart Association hosted a congressional briefing on March 21 to inform lawmakers about these advances in psoriatic disease research.
Rep. Jim Gerlach, R-Pa., a longtime champion of psoriatic disease research who introduced psoriasis and psoriatic arthritis legislation in the U.S. House of Representatives last year, opened the briefing to representatives from more than 30 congressional offices.
Dr. Stephen Katz—the director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the federal agency that researches diseases of the bones, joints, muscles and skin—shared the latest psoriatic disease research from the National Institutes of Health.
Other speakers included Richard Seiden, immediate past chair of the National Psoriasis Foundation Board of Trustees, who spoke about living with severe psoriatic arthritis and being diagnosed with diabetes. Cardiologist Dr. Erin Michos of Johns Hopkins University gave an overview of the risk factors and potential adverse cardiovascular effects of psoriasis.
Research into the connection between psoriasis and psoriatic arthritis and other comorbidities is a key priority of the first public health agenda for psoriatic diseases that was released in February by the Centers for Disease Control and Prevention. At the briefing, the Psoriasis Foundation encouraged the attendees to consider how we could build upon the success of this agenda and continue funding public health research into these diseases
April 9, 2013